ProfileGDS5678 / 1425852_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 33% 33% 34% 32% 29% 35% 44% 33% 33% 33% 34% 33% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7082430
GSM967853U87-EV human glioblastoma xenograft - Control 22.7588633
GSM967854U87-EV human glioblastoma xenograft - Control 32.7560333
GSM967855U87-EV human glioblastoma xenograft - Control 42.7112634
GSM967856U87-EV human glioblastoma xenograft - Control 52.6834332
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7354129
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8632535
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0268644
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7191633
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7454133
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7448533
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7302234
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7562533
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.764634